Total
0
Shares
LBT Innovations (ASX:LBT) - CEO and MD, Brent Barnes
CEO and MD, Brent Barnes
Source: LBT Innovations
Market Herald logo

Subscribe

Be the first with the news that moves the market
  • LBT Innovations (LBT) 50 per cent owned joint venture company, Clever Culture System, appoints Thermo Fisher Scientific as its US distributor
  • Under the five-year agreement, Thermo Fisher will exclusively distribute LBT’s APAS Independence in the United States
  • Thermo Fisher will also engage in sales, marketing and related activities as well as provide installation, maintenance and support services to its US customers
  • APAS Independence speeds-up culture plate screening by automatically screening, interpreting and sorting the plates
  • LBT is up 10.7 per cent on the market with shares trading at 15.5 cents at 11:15 am AEST

LBT Innovations (LBT) 50 per cent owned joint venture company, Clever Culture System (CCS), has appointed Thermo Fisher Scientific as its US distributor.

Under the five-year agreement, Thermo Fisher will exclusively distribute LBT’s APAS Independence in the United States.

CEO and Managing Director Brent Barnes said this was a major achievement for the company as it would provide a footprint to increase sales and commercial activities in the country.

“This is a really important milestone for LBT and represents a major step forward in our commercialisation strategy in the United States,” Mr Barnes commented.

“We have spoken previously about the importance of appointing well recognised, leading distributors to support our sales efforts in key markets.”

“We are very pleased to now have two of the world’s largest microbiology companies selling our technology across the two main markets of the United States and Europe, which is a further validation of benefits of our technology.”

Under the agreement, Thermo Fisher will engage in sales, marketing and related activities for APAS Independence.

Additionally, the company will also provide installation, maintenance and support services to its US customers.

Thermo Fisher President Christophe Fraudeau commented on the agreement.

“Our customers need smart automation products that deliver real workflow efficiencies and the APAS Independence does just that by using artificial intelligence to provide active decision-making that reduces workload and enables laboratories to streamline their workflows,” Mr Fraudeau said.

APAS (Automated Plate Assessment System) Independence is a platform technology that automates culture-plate screening and interpretation.

Thousands of agar plates are assessed every day and each one has to be thoroughly examined by a microbiologist.

APAS Independence speeds up this process by automatically screening, interpreting and sorting the plates – freeing up the microbiologist’s time.

LBT was up 10.7 per cent on the market with shares trading at 15.5 cents at 11:15 am AEST.

LBT by the numbers
More From The Market Herald
Zelira Therapeutics (ASX:ZLD) - CEO and MD, Dr Oludare Odumosu

" Zelira Therapeutics (ASX:ZLD) recieves funding from Quincy Street

Zelira Therapeutics (ZLD) has raised US$5 million (around A$6.68) from US family office fund, Quincy Street Capital.
Advanced Human Imaging (ASX:AHI) - CEO, Vlado Bosanac

" Advanced Human Imaging (ASX:AHI) pushes ahead with NASDAQ listing

Advanced Human Imaging (AHI) is pushing ahead with a planned NASDAQ listing, after filing a key form with the US Securities and Exchange
Opthea (ASX:OPT) - CEO and MD, Megan Baldwin

" Opthea (ASX:OPT) opens patient enrolment in Asia-Pacific

Opthea (OPT) has opened patient enrolment for its Phase 3 clinical program for the treatment of wet (neovascular) age-related macular degeneration (AMD) in

" TruScreen (ASX:TRU) highlights efficacy of cancer screening technology

TruScreen (TRU) says the results of a new study demonstrate its cervical cancer screening technology to be an effective alternative to other screening